secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001193125-22-145661
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer acquires Biohaven for $11.6B cash; gains migraine portfolio NURTEC ODT
-----------------------------------------------------------------------------

- Total consideration ~$11.6B: $148.50/share cash + 0.5 share of New Biohaven per Biohaven share.
- Acquires NURTEC ODT (rimegepant) approved for acute & preventive migraine, plus zavegepant & preclinical CGRP assets.
- New Biohaven (SpinCo) retains non-CGRP pipeline, capitalized with $275M; eligible for tiered royalties on US sales >$5.25B.
- Cash consideration represents ~33% premium to 3-month VWAP; closing expected early 2023, subject to approvals.
- Pfizer also to repay Biohaven's $1.26B debt and redeem preferred shares at closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000119312522145661/0001193125-22-145661-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000119312522145661/d336582d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-145661

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer